Core Viewpoint - ZipRecruiter, Inc. (ZIP) has seen a 5.3% increase in share price over the past four weeks, closing at $5.59, with analysts suggesting a potential upside of 43.1% based on a mean price target of $8 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.87, indicating variability among analysts; the lowest estimate is $6 (7.3% increase), while the highest is $10 (78.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases; the Zacks Consensus Estimate for the current year has risen by 1.1% over the past month [4][11][12] - ZipRecruiter holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13]

Group 1 - Birkenstock (BIRK) shares have increased by 9.6% over the past four weeks, closing at $55.05, with a mean price target of $68.88 indicating a potential upside of 25.1% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $81, with a standard deviation of $7.34, suggesting a relatively high agreement among analysts [2] - Analysts have shown increasing optimism regarding BIRK's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for BIRK's current year earnings has risen by 3.4% over the past month, with seven estimates increasing and two decreasing [12] - BIRK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Group 1 - Perrigo's shares have increased by 8.8% over the past four weeks, closing at $26.91, with a mean price target of $34.25 indicating a potential upside of 27.3% [1] - The mean estimate includes four short-term price targets with a standard deviation of $6.95, where the lowest estimate suggests a 0.3% increase and the highest predicts a 56.1% surge to $42 [2] - Analysts show a consensus that Perrigo will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.5%, with two estimates moving higher and one lower over the last 30 days [12] - Perrigo holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets should not be the sole basis for investment decisions, the direction implied by these targets can serve as a useful guide for further research [10][11]

Summary of Key Points Core Viewpoint - Knightscope, Inc. (KSCP) has seen a significant stock price increase of 26.4% over the past four weeks, closing at $5.84, with analysts suggesting a potential upside of 191.1% based on a mean price target of $17 [1]. Price Targets and Analyst Consensus - The average price target for KSCP ranges from a low of $9 to a high of $30, with a standard deviation of $11.36, indicating variability in analyst estimates. The lowest estimate suggests a 54.1% increase, while the highest points to a 413.7% upside [2]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about KSCP's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11]. - Over the past 30 days, one earnings estimate has increased, leading to a 4.7% rise in the Zacks Consensus Estimate for the current year [12]. Zacks Rank and Investment Potential - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13].

Group 1 - The RealReal (REAL) shares have increased by 3% over the past four weeks, closing at $5.43, with a mean price target of $10.10 indicating a potential upside of 86% [1] - The average price targets range from a low of $7 to a high of $15, with a standard deviation of $3.09, suggesting a variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 64.3%, indicating a positive outlook for the company's earnings [12] - REAL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside [13]

Core Viewpoint - Accel Entertainment (ACEL) shares have increased by 4.1% recently, with analysts suggesting a potential upside of 36.7% based on a mean price target of $15.67 [1][11]. Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $0.58, indicating a consensus among analysts [2]. - The lowest estimate is $15, suggesting a 30.9% increase, while the highest estimate is $16, indicating a 39.6% increase from the current price [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ACEL's earnings prospects, as indicated by upward revisions in EPS estimates, which have shown a strong correlation with stock price movements [11]. - Over the past 30 days, two earnings estimates have been revised upward, leading to an 8% increase in the Zacks Consensus Estimate [12]. - ACEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13].

Core Viewpoint - West Pharmaceutical Services (WST) has seen a 7.3% increase in share price over the past four weeks, closing at $216.64, with a potential upside of 31.1% based on Wall Street analysts' mean price target of $284 [1] Price Targets and Analyst Consensus - The average of 10 short-term price targets ranges from a low of $245 to a high of $355, with a standard deviation of $34.94, indicating variability in estimates [2] - The lowest estimate suggests a 13.1% increase, while the highest points to a 63.9% upside, highlighting the range of analyst expectations [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 1.9% over the past month, with five estimates increasing and no negative revisions [12] - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Core Viewpoint - AtriCure (ATRC) shows potential for significant upside, with a mean price target of $49.89 indicating a 54.7% increase from its current price of $32.25 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.37, suggesting variability among analysts [2] - The lowest estimate of $40 indicates a 24% increase, while the highest estimate suggests an 86.1% surge to $60 [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AtriCure's earnings, with a positive trend in earnings estimate revisions indicating potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.1%, with four estimates moving higher and no negative revisions [12] - AtriCure holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research [10]

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has seen a 14.9% increase in share price over the past four weeks, closing at $7.88, with a potential upside of 408.6% based on Wall Street analysts' mean price target of $40.08 [1] Price Targets and Estimates - The mean estimate consists of 25 short-term price targets with a standard deviation of $26.66, indicating variability among analysts; the lowest estimate is $9 (14.2% increase), while the highest is $106 (1245.2% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising NTLA's earnings estimates higher, which correlates with potential stock price increases; the Zacks Consensus Estimate for the current year has risen by 7.6% over the last 30 days [4][11][12] - NTLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a solid potential upside [13]

Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at $17.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.14 indicates a potential upside of 105.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 57.9% increase from the current pric ...